Last edition
News about "Tejash Hathi"
Aptus Pharma plans its next growth phase with a INR 44.88 crore preferential equity issue, focusing on manufacturing, pan-India expansion and global markets.
Tejash Hathi | 24/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members